466 related articles for article (PubMed ID: 23258593)
1. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury.
Chen M; Borlak J; Tong W
Hepatology; 2013 Jul; 58(1):388-96. PubMed ID: 23258593
[TBL] [Abstract][Full Text] [Related]
2. Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury.
McEuen K; Borlak J; Tong W; Chen M
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640208
[TBL] [Abstract][Full Text] [Related]
3. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals.
Lammert C; Einarsson S; Saha C; Niklasson A; Bjornsson E; Chalasani N
Hepatology; 2008 Jun; 47(6):2003-9. PubMed ID: 18454504
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications.
Weng Z; Wang K; Li H; Shi Q
Oncotarget; 2015 Jul; 6(19):17031-8. PubMed ID: 26220713
[TBL] [Abstract][Full Text] [Related]
5. A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the 'rule-of-two' model.
Chen M; Tung CW; Shi Q; Guo L; Shi L; Fang H; Borlak J; Tong W
Arch Toxicol; 2014 Jul; 88(7):1439-49. PubMed ID: 24958025
[TBL] [Abstract][Full Text] [Related]
6. FDA-approved drug labeling for the study of drug-induced liver injury.
Chen M; Vijay V; Shi Q; Liu Z; Fang H; Tong W
Drug Discov Today; 2011 Aug; 16(15-16):697-703. PubMed ID: 21624500
[TBL] [Abstract][Full Text] [Related]
7. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs.
Chen M; Hong H; Fang H; Kelly R; Zhou G; Borlak J; Tong W
Toxicol Sci; 2013 Nov; 136(1):242-9. PubMed ID: 23997115
[TBL] [Abstract][Full Text] [Related]
8. A Model to predict severity of drug-induced liver injury in humans.
Chen M; Borlak J; Tong W
Hepatology; 2016 Sep; 64(3):931-40. PubMed ID: 27302180
[TBL] [Abstract][Full Text] [Related]
9. Safety data and withdrawal of hepatotoxic drugs.
Babai S; Auclert L; Le-Louët H
Therapie; 2021; 76(6):715-723. PubMed ID: 29609830
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Drug-Induced Liver Injury Prediction: Criteria Optimization of Efflux Transporter IC50 and Physicochemical Properties.
Yucha RW; He K; Shi Q; Cai L; Nakashita Y; Xia CQ; Liao M
Toxicol Sci; 2017 Jun; 157(2):487-499. PubMed ID: 28369588
[TBL] [Abstract][Full Text] [Related]
11. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
[TBL] [Abstract][Full Text] [Related]
12. A high content screening assay to predict human drug-induced liver injury during drug discovery.
Persson M; Løye AF; Mow T; Hornberg JJ
J Pharmacol Toxicol Methods; 2013; 68(3):302-13. PubMed ID: 23933113
[TBL] [Abstract][Full Text] [Related]
13. Hepatotoxicity by Drugs: The Most Common Implicated Agents.
Björnsson ES
Int J Mol Sci; 2016 Feb; 17(2):224. PubMed ID: 26861310
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced liver injury: what was new in 2013?
Chalhoub WM; Sliman KD; Arumuganathan M; Lewis JH
Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):959-80. PubMed ID: 24746272
[TBL] [Abstract][Full Text] [Related]
15. Development of a Battery of
Rathman J; Yang C; Ribeiro JV; Mostrag A; Thakkar S; Tong W; Hobocienski B; Sacher O; Magdziarz T; Bienfait B
Chem Res Toxicol; 2021 Feb; 34(2):601-615. PubMed ID: 33356149
[TBL] [Abstract][Full Text] [Related]
16. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.
Suzuki A; Andrade RJ; Bjornsson E; Lucena MI; Lee WM; Yuen NA; Hunt CM; Freston JW
Drug Saf; 2010 Jun; 33(6):503-22. PubMed ID: 20486732
[TBL] [Abstract][Full Text] [Related]
17. Impact of Physicochemical Properties on Dose and Hepatotoxicity of Oral Drugs.
Leeson PD
Chem Res Toxicol; 2018 Jun; 31(6):494-505. PubMed ID: 29722540
[TBL] [Abstract][Full Text] [Related]
18. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Sakatis MZ; Reese MJ; Harrell AW; Taylor MA; Baines IA; Chen L; Bloomer JC; Yang EY; Ellens HM; Ambroso JL; Lovatt CA; Ayrton AD; Clarke SE
Chem Res Toxicol; 2012 Oct; 25(10):2067-82. PubMed ID: 22931300
[TBL] [Abstract][Full Text] [Related]
19. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events.
Lammert C; Bjornsson E; Niklasson A; Chalasani N
Hepatology; 2010 Feb; 51(2):615-20. PubMed ID: 19839004
[TBL] [Abstract][Full Text] [Related]
20. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury.
Yu K; Geng X; Chen M; Zhang J; Wang B; Ilic K; Tong W
Drug Metab Dispos; 2014 Apr; 42(4):744-50. PubMed ID: 24464804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
